ACCESS Newswire

Peptomyc SL

28.7.2023 00:01:41 CEST | ACCESS Newswire | Press release

Share
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

OMO-103 in Phase 1b clinical trial

BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Peptomyc logo
Peptomyc logo



MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".

This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Muñoz at the Hospital Gregorio Marañon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

Contact Information

Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869

SOURCE: Peptomyc SL

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/770698/Peptomyc-Announces-the-Approval-of-Its-Phase-1b-Trial-Testing-OMO-103-in-Combination-With-Standard-of-Care-in-PDAC-Patients

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Tech "Talent Wars" Are Over as More Companies Prioritize Upskilling, General Assembly Report Finds25.2.2026 15:00:00 CET | Press release

83% of tech recruiters believe company success is more dependent on upskilling employees for AI versus hiring new talent, according to The State of Tech Talent 2026 NEW YORK CITY, NY / ACCESS Newswire / February 25, 2026 / Nearly all technology recruiters (96%) say technical roles are still at least a bit difficult to fill, as most (83%) believe their company's success is now more dependent on upskilling their existing employees for AI rather than hiring external talent, according to The State of Tech Talent 2026, the fourth annual report from AI training provider General Assembly, an LHH brand. "The AI skills gap is growing too fast for companies to hire their way out," said Daniele Grassi, CEO of General Assembly. "Continuous, incremental and role-specific learning is the only way to keep up with the pace of technology change. Growing investment in upskilling reflects leaders' realization that their existing employees bring the business context, institutional knowledge and cultural n

Around Half of Firms' Revenue Depends on Winning RFPs, but Many Lack Scalable Proposal Management Processes, QorusDocs Study Finds25.2.2026 15:00:00 CET | Press release

63% report higher RFP volumes - but up to 20% go unfinished due to resource constraints as proposal teams see 25 to 50% workload spikes SEATTLE, WA / ACCESS Newswire / February 25, 2026 / As B2B buying has become more structured, consensus-driven and risk-averse, proposals and RFPs have moved from a back-office task to a primary driver of revenue at professional services firms, according to new research from QorusDocs, a leader in AI-powered value and proposal management software. Once viewed as a downstream support function, proposal management, now directly shapes pipeline health, win rates and revenue outcomes. As AI disrupts the traditional billable-hour model and prompts corporate clients to question fees, proposal operations have emerged as a critical lever to protect margins and capture growth. However, growing RFP volumes have driven a 25 to 50% workload spike for proposal teams at most organizations. "Time, not intent, has become the primary constraint for modern proposal team

Assembly Chosen to Power Global Paid Media and Amazon Growth for Jabra24.2.2026 15:50:00 CET | Press release

LONDON, GB / ACCESS Newswire / February 24, 2026 / Assembly, the global omnichannel agency built to make brands perform, has been appointed by Jabra, world leading brand in audio, video, and collaboration solutions, as its global paid media agency and lead partner for Amazon services following a competitive pitch process. Assembly's remit spans full-funnel paid media across search, social, display, video, and retail media, alongside Amazon strategy and marketplace operations, to fuel Jabra's next phase of global growth. Pitch Consultants, Tuffon Hall Consultancy, commented: "This was an exceptionally competitive process, and Jabra's new move towards a direct-to-consumer model marks a major shift for the business. Assembly impressed with a powerful proposition, using their proprietary platform STAGE to create a true intelligence engine for Jabra that supports smarter, more connected growth." Why Jabra chose Assembly Assembly was selected for its ability to connect brand and performance,

GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B23.2.2026 13:10:00 CET | Press release

Industry Leading UAS Expands Mission Roles To Include Naval Strike SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®. Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons. "MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long

GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise23.2.2026 13:05:00 CET | Press release

SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms. The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands. "We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to ut

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye